Cargando…
Do genetics contribute to TNF inhibitor response prediction in Psoriatic Arthritis?
Psoriatic arthritis (PsA) is a heterogeneous chronic musculoskeletal disease, affecting up to 30% of people with psoriasis. Research into PsA pathogenesis has led to the development of targeted therapies, including Tumor Necrosis Factor inhibitors (TNF-i). Good response is only achieved by ~60% of p...
Autores principales: | Curry, Philippa D. K., Morris, Andrew P., Barton, Anne, Bluett, James |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
Nature Publishing Group UK
2022
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9925377/ https://www.ncbi.nlm.nih.gov/pubmed/36243888 http://dx.doi.org/10.1038/s41397-022-00290-8 |
Ejemplares similares
-
Therapeutic monitoring of TNF inhibitors for rheumatoid arthritis: evidence required following NICE’s recommendations
por: Gavan, Sean P, et al.
Publicado: (2020) -
Pharmacogenetics of TNF inhibitor response in rheumatoid arthritis utilizing the two-component disease activity score
por: Gilani, Syed SA, et al.
Publicado: (2020) -
Psoriatic arthritis: review of potential biomarkers predicting response to TNF inhibitors
por: Makos, Anaïs, et al.
Publicado: (2022) -
Genetic epidemiology: Psoriatic arthritis
por: Barton, Anne C
Publicado: (2002) -
Role of golimumab, a TNF-alpha inhibitor, in the treatment of the psoriatic arthritis
por: Michelon, Melissa A, et al.
Publicado: (2010)